Glenn David is executive vice president and group president of Zoetis, the world leader in animal health. In this role, he is responsible for overseeing Zoetis’ international operations, aquaculture business (PHARMAQ), Global BioDevices, and Pumpkin Pet Insurance.
As a business leader in animal health for a decade, Mr. David brings broad industry experience to running businesses and making investments that have driven Zoetis’ growth. As a member of the Zoetis Executive team since 2016, he has played a pivotal role in supporting the company’s recent product launches, scrutinizing new business opportunities, and investing in global expansion initiatives.
Mr. David previously served as the company’s Chief Financial Officer from 2016 until June 2021, leading a diverse global team of finance professionals across 45 markets. In that role, he had responsibility for financial planning, external reporting, investor relations, treasury, tax, global operations and the company’s business development efforts. During his tenure as CFO, the company maintained a well-capitalized and financially disciplined business, creating significant value for shareholders.
Earlier in his career, Mr. David served as senior vice president of Finance Operations for Zoetis during its Initial Public Offering in 2013. From April 2014 through August 2014, Mr. David served as acting Chief Financial Officer of Zoetis, overseeing financial management, reporting and shareholder relations and global procurement and operations.
Before the Zoetis IPO, Mr. David served in various financial roles at Pfizer, including vice president of Global Finance for Pfizer Animal Health and vice president of Finance for the U.S. Primary Care franchise. Mr. David also played important financial roles in Pfizer’s integration of the Pharmacia, Wyeth and King Pharmaceuticals’ acquisitions. Prior to joining Pfizer in 1999, Mr. David gained valuable financial experience at Bankers Trust, Paine Webber and Credit Suisse.
Mr. David graduated magna cum laude with a bachelor’s degree in Finance from Binghamton University, and earned his MBA in Finance/Information Technology from New York University.
What is Glenn David's net worth?
The estimated net worth of Glenn David is at least $6.55 million as of March 5th, 2020. Mr. David owns 36,885 shares of Zoetis stock worth more than $6,554,096 as of December 3rd. This net worth evaluation does not reflect any other assets that Mr. David may own. Learn More about Glenn David's net worth.
How do I contact Glenn David?
Has Glenn David been buying or selling shares of Zoetis?
Glenn David has not been actively trading shares of Zoetis in the last ninety days. Most recently, Glenn David sold 32,390 shares of the business's stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $189.87, for a transaction totalling $6,149,889.30. Learn More on Glenn David's trading history.
Who are Zoetis' active insiders?
Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO & Director), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?
In the last twelve months, insiders at the sold shares 5 times. They sold a total of 5,632 shares worth more than $1,047,983.01. The most recent insider tranaction occured on April, 18th when EVP Roxanne Lagano sold 923 shares worth more than $139,529.91. Insiders at Zoetis own 0.2% of the company.
Learn More about insider trades at Zoetis. Information on this page was last updated on 4/18/2024.
